Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. April 2026 16:02 ET | Quelle: Revolution Medicines, Inc.

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
17. April 2026 08:05 ET | Quelle: First Steps Developmental Services

First Steps Developmental Services Expands Services in Woburn

First Steps Developmental Services launches two new ABA programs in Woburn, MA — no waitlist for children with Autism ages 0–6.
16. April 2026 09:20 ET | Quelle: MAIA Biotechnology, Inc.

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC...
16. April 2026 09:00 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc....
16. April 2026 07:30 ET | Quelle: EDAP TMS S.A.

EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN,...
16. April 2026 03:00 ET | Quelle: STORM Therapeutics

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

STORM Therapeutics announces a $56 million Series C financing to support the advancement of STC-15 in a Phase 2 study.
16. April 2026 00:30 ET | Quelle: Custom Market Insights

[Latest] Global Vacuum Skin Packaging Market Size/Share Worth USD 35.1 Billion by 2035 at a 3.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, April 16, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Vacuum Skin Packaging Market Size, Trends and Insights By Type (Flat Skin...
15. April 2026 11:00 ET | Quelle: Institute of Molecular and Clinical Ophthalmology Basel (IOB)

What if you could reboot sick cells?

Researchers at IOB developed targeted delivery of healthy mitochondria to diseased cells, opening new paths for treating mitochondrial disorders.
15. April 2026 08:00 ET | Quelle: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
15. April 2026 08:00 ET | Quelle: Boehringer Ingelheim Limited

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). ...

Vorherige Seite